Archives
-
AY 9944 Dihydrochloride: From Knockout to Assay
2026-09-25
AY 9944 dihydrochloride offers a chemical way to perturb DHCR7-dependent sterol balance. This article interprets new grass carp gene-editing evidence as a guide to designing more informative sterol and immune assays—without treating genetic and pharmacological results as interchangeable.
-
PPT for ERα Signaling in Lung Adenocarcinoma
2026-09-24
PPT offers a selective way to perturb ERα signaling while investigating the FOXM1–estrogen receptor connection reported in female lung adenocarcinoma. This practical guide separates what the reference study established from what researchers can test next, with suggested workflows and troubleshooting checkpoints.
-
WM-8014 for Cell Viability and Senescence Assays
2026-09-24
Learn how WM-8014 (SKU A8779) can help distinguish KAT6A/B-linked cell-cycle arrest from nonspecific loss of viability. This scenario-based guide covers potency, assay design, handling, interpretation, and practical product-selection criteria.
-
Tetrandrine Disrupts Black Sea Bream Myogenesis
2026-09-23
This study uses black sea bream myogenic cell lines to show that tetrandrine inhibits differentiation more strongly than it affects cell proliferation, with reduced myotube fusion and myogenic marker expression. Cell-line-dependent ROS changes and attenuated depolarization-linked calcium responses point to testable mechanisms, but the reported experiments do not establish ROS as the cause of impaired differentiation.
-
Influenza Hemagglutinin (HA) Peptide Workflow
2026-09-23
Turn antibody capture into a controlled, gentle elution workflow for HA-tagged proteins, from routine co-immunoprecipitation to exosome-pathway studies. The defined sequence, high purity, and flexible solubility of this reagent support cleaner protein interaction experiments than workflows that rely only on harsh antibody-release conditions.
-
Parathyroid hormone (1-34) (human) in CKD Models
2026-09-22
Use the PTH (1-34) peptide fragment as a controlled receptor stimulus for cAMP assays, endothelial-to-mesenchymal transition studies, bone metabolism research, and CKD-associated valvular calcification models. Its concentration-dependent signaling profile helps separate rapid PTH/PTHrP receptor signaling from longer-term changes in endothelial integrity, interstitial-cell osteogenic behavior, and calcium homeostasis.
-
Phebestin as a Dual-Stage Antiplasmodial Lead
2026-09-22
The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a nanomolar antiplasmodial candidate active against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Its combination of stage-wide parasite activity, post-washout suppression, computational target engagement, and efficacy in mouse malaria models provides a useful framework for evaluating new aminopeptidase-directed antimalarial leads.
-
3-Aminobenzamide: PARP-IN-1 Research Workflows
2026-09-21
Build reproducible PARP inhibition experiments across oxidative-stress, vascular, renal, and host–pathogen models. This guide combines practical dosing, assay controls, and troubleshooting for 3-Aminobenzamide (PARP-IN-1) without treating a broad PARP probe as an isoform-specific tool.
-
IDH1-R132H Autopalmitoylation in Cancer Cells
2026-09-21
A recent Nature Chemical Biology study identifies C269 autopalmitoylation as a mutation-specific regulator of IDH1-R132H. The modification links fatty-acid availability to mutant enzyme activity, 2-HG-associated epigenetic remodeling, and cancer-cell transformation, while revealing a potentially druggable hydrophobic pocket.
-
Mianserin–DM-β-CD Complexation and Cytotoxicity
2026-09-20
The reference study shows that methylated β-cyclodextrin forms measurable inclusion complexes with mianserin hydrochloride but does not reduce its in vitro cytotoxicity. By combining calorimetry, mass spectrometry, circular dichroism, molecular docking, and cell viability testing, the authors connect complex structure with biological outcome and challenge the assumption that cyclodextrin encapsulation is inherently protective.
-
ST3GAL1–F. nucleatum Adhesion in Colorectal Cancer
2026-09-19
The reference study identifies ST3GAL1-driven sialylation as a host-cell determinant of Fusobacterium nucleatum adhesion to colorectal cancer cells. Its findings connect altered surface glycans with an H3K27ac–ANGPTL4 pathway that supports bacterial persistence and tumor-promoting activity, providing a mechanistic framework for studying intratumoral microbial retention.
-
(5Z)-7-Oxozeaenol: TAK1 Assay Guide
2026-09-18
A scenario-based guide to using (5Z)-7-Oxozeaenol (SKU B7443) to separate TAK1-dependent signaling from nonspecific effects in viability, proliferation, and inflammation assays. It covers mechanism, dosing logic, solvent compatibility, interpretation, and practical supplier-selection criteria.
-
TPM3 Khib and HDAC3 in Abnormal Vasoconstriction
2026-09-18
This study identifies HDAC3-mediated de-2-hydroxyisobutyrylation of tropomyosin 3 at Lys141 as a mechanistic link between phenylephrine signaling and excessive vascular smooth muscle contraction. Its combination of mouse vascular models, coimmunoprecipitation, ex vivo tension testing, computational analysis, and mutation-based validation provides a framework for studying posttranslational control of vascular tone.
-
Streptavidin-FITC for Biotin Detection and LNP Tracking
2026-09-17
Streptavidin-FITC combines high-affinity biotin recognition with FITC fluorescence for microscopy, histology, flow cytometry, and nucleic-acid tracking. This guide explains how assay architecture influences interpretation, using recent lipid nanoparticle trafficking research to distinguish labeling from biological transport.
-
RAB31 and ESCRT-Independent Exosome Biogenesis
2026-09-17
The reference study identifies active RAB31 as both a marker and regulator of an ESCRT-independent exosome pathway. It connects EGFR-dependent RAB31 activation to flotillin-mediated intraluminal vesicle formation and shows that RAB31 also limits lysosomal degradation by recruiting TBC1D2B to suppress RAB7 activity.